Either BD Cytofix™ fixation buffer or BD™ Phosflow Fix Buffer I may be used for cell fixation. Any of the three BD™ Phosflow permeabilization buffers may be used.
Probenmenge
20 μL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Target
PKA RIIalpha
Andere Bezeichnung
PKA RIIa
Hintergrund
CAMP-dependent Protein Kinase (PKA) is composed of two distinct subunits: catalytic (C) and regulatory (R). Four regulatory subunits have been identified: RIalpha, RIbeta, RIIalpha, and RIIbeta. These subunits define type I and II PKAs. Following binding of cAMP, the regulatory subunits dissociate from the catalytic subunits, rendering the enzyme active. Type I and II holoenzymes have three potential C subunits (Calpha, Cbeta, or Cgamma). Type II PKA can be distinguished by autophosphorylation of the R subunits, while type I PKA binds Mg/ATP with high affinity. The cAMP-dependent autophosphorylation of the human RIIalpha subunit occurs at Serine 99 (S99) [Entrez Protein Accession #CAA33094]. Most cells express both type I and type II PKAs. Although the Ralpha isoforms are ubiquitously expressed, the Rbeta isoforms are predominantly found in nervous and adipose tissues. In addition to their enzyme regulatory activity, the RIIalpha and RIIbeta subunits determine the subcellular location of the holoenzymes via their interactions with specific intracellular anchoring proteins. The I65-856.286 antibody recognizes human PKA RIIalpha phosphorylated at S99.